May 29, 2024 7:00am EDT Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 08, 2024 7:00am EDT Immunocore reports first quarter financial results and provides a business update
Feb 28, 2024 7:34am EST Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
Feb 22, 2024 7:00am EST Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
Feb 21, 2024 7:00am EST Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024